Therapy Areas: Inflammatory Diseases
Hoth Therapeutics files two US provisional patent applications to establish oncology-focused dermatology platform
5 January 2026 - Hoth Therapeutics (NASDAQ:HOTH), a US-based clinical-stage biopharmaceutical company focused on developing innovative therapies for underserved medical needs, announced on Friday an e...
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
2 January 2026 - Animal health specialist Elanco Animal Health Incorporated (NYSE:ELAN) announced on Wednesday that it has received approval from the US Department of Agriculture (USDA) for Befrena (t...
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
23 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) on Tuesday announced approval from J...
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
23 December 2025 - Clinical-stage immunotherapeutics company Aqualung Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a Phase 2a study...
Alvotech launches first-in-market golimumab biosimilar in Europe
22 December 2025 - Global biotechnology company Alvotech S.A. (NASDAQ:ALVO) announced on Monday the European launch of Gobivaz (golimumab), its biosimilar to Simponi (golimumab), also known as AVT05 (...
Physiomics secures follow-on UK contract for Phase 2 study support
15 December 2025 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Monday that it has been awarded a follow-on contract with an existing UK cl...